Fresh analysis suggests that individuals who come off new GLP-1 drugs like semaglutide or tirzepatide tend to recover shed pounds at a significantly accelerated pace than those who halt traditional lifestyle plans.
Published data in a prominent medical journal shows that while obese individuals often shed about a fifth of their body weight while undergoing treatment, the weight is regained at an average rate of 0.8 kg per month upon discontinuation.
"Users using such drugs must be cognizant of the potential of fast weight regain when the treatment is stopped," cautioned expert Dr. Susan Jebb.
This pace of regain implies a reversion to starting mass in about one and a half years.
Analyzing Therapies
The study, which examined 37 of studies involving thousands of patients, compared the outcomes of the injectable medications with older methods.
Scientists note that people who lose weight through lifestyle changes alone generally experience a more gradual weight regain—approximately 100 grams monthly—after stopping.
Explaining the Quick Regain
Doctors suggest the mode of action of the jabs is key to understanding the amplified regain.
The injections copy a natural hormone called GLP-1, which helps regulate appetite.
"Sustained high doses of the hormone levels far above than normal might result in the system to produce less of its endogenous hormone, and could lessen sensitivity to its effects," noted Dr. Adam Collins, a nutrition researcher.
"Stopping of this GLP-1 'fix' means appetite is uncontrolled, making binge eating far more likely."
A Lifelong Issue?
Medical guidelines suggest the injections for people with weight-linked health risks, accompanied by recommended diet and exercise modifications.
Many experts argue that, considering the high risk of weight regain, the therapy is often life-long.
This opinion is echoed by drug manufacturers, who state that the findings "underscore the persistent character of obesity," akin to managing diseases like high blood pressure.
Patient Accounts
Users who have stopped the medication explain a sudden return of hunger.
"I experienced something flipping and you're instantly extremely hungry," described one woman.
This difficulty is compounded if patients have not adopted lasting dietary or behavioural changes during treatment.
Widespread Use
Recent estimates suggest that millions of people in the UK have tried weight-loss jabs in the past year, with desire continuing to grow.
- Adoption is more common among women compared to males.
- The middle-aged demographic shows the highest usage rates.
- A large proportion obtain the medications through private healthcare rather than public health services.
In conclusion, clinicians emphasize that while the jabs are powerful tools for shedding pounds, they are not a permanent cure and maintained weight loss hinges on ongoing lifestyle support.
